630 related articles for article (PubMed ID: 26968675)
1. Bitter melon: a panacea for inflammation and cancer.
Dandawate PR; Subramaniam D; Padhye SB; Anant S
Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
[TBL] [Abstract][Full Text] [Related]
2. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
Raina K; Kumar D; Agarwal R
Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
[TBL] [Abstract][Full Text] [Related]
3. Anti-Inflammatory, Antidiabetic Properties and In Silico Modeling of Cucurbitane-Type Triterpene Glycosides from Fruits of an Indian Cultivar of
Perera WH; Shivanagoudra SR; Pérez JL; Kim DM; Sun Y; K Jayaprakasha G; S Patil B
Molecules; 2021 Feb; 26(4):. PubMed ID: 33669312
[TBL] [Abstract][Full Text] [Related]
4. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia).
Fang EF; Froetscher L; Scheibye-Knudsen M; Bohr VA; Wong JH; Ng TB
Curr Protein Pept Sci; 2019; 20(3):296-301. PubMed ID: 29932035
[TBL] [Abstract][Full Text] [Related]
5. An Update Review on the Anthelmintic Activity of Bitter Gourd,
Poolperm S; Jiraungkoorskul W
Pharmacogn Rev; 2017; 11(21):31-34. PubMed ID: 28503051
[No Abstract] [Full Text] [Related]
6. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
7. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats.
Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y
J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725
[TBL] [Abstract][Full Text] [Related]
8. Bitter Melon (
Sur S; Ray RB
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726914
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitane-type compounds from Momordica charantia: Isolation, in vitro antidiabetic, anti-inflammatory activities and in silico modeling approaches.
Shivanagoudra SR; Perera WH; Perez JL; Athrey G; Sun Y; Jayaprakasha GK; Patil BS
Bioorg Chem; 2019 Jun; 87():31-42. PubMed ID: 30856374
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Biological Activities of Wild Bitter Melon (
Pham TMH; Ngo DH; Ngo DN; Vo TS
Biomolecules; 2019 May; 9(6):. PubMed ID: 31151277
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitane triterpenoids from the fruit of Momordica charantia L. and their anti-hepatic fibrosis and anti-hepatoma activities.
Yue J; Sun Y; Xu J; Cao J; Chen G; Zhang H; Zhang X; Zhao Y
Phytochemistry; 2019 Jan; 157():21-27. PubMed ID: 30352327
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of Charantin and Expression of Triterpenoid Biosynthesis Genes in Bitter Melon (Momordica charantia).
Cuong DM; Jeon J; Morgan AMA; Kim C; Kim JK; Lee SY; Park SU
J Agric Food Chem; 2017 Aug; 65(33):7240-7249. PubMed ID: 28737900
[TBL] [Abstract][Full Text] [Related]
13. Structure determination, bitterness evaluation and hepatic gluconeogenesis inhibitory activity of triterpenoids from the Momordica charantia fruit.
Deng Y; Ma Y; Liu H; Zhang Y; Wei Z; Liu G; Tang X; Jia X
Food Chem; 2022 Mar; 372():131224. PubMed ID: 34624787
[TBL] [Abstract][Full Text] [Related]
14. Bitter gourd (Momordica charantia) as a rich source of bioactive components to combat cancer naturally: Are we on the right track to fully unlock its potential as inhibitor of deregulated signaling pathways.
Farooqi AA; Khalid S; Tahir F; Sabitaliyevich UY; Yaylim I; Attar R; Xu B
Food Chem Toxicol; 2018 Sep; 119():98-105. PubMed ID: 29753870
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitane-type triterpenoids from the stems and leaves of Momordica charantia.
Zhao GT; Liu JQ; Deng YY; Li HZ; Chen JC; Zhang ZR; Zhou L; Qiu MH
Fitoterapia; 2014 Jun; 95():75-82. PubMed ID: 24631764
[TBL] [Abstract][Full Text] [Related]
16.
Bortolotti M; Mercatelli D; Polito L
Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
[No Abstract] [Full Text] [Related]
17. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
[TBL] [Abstract][Full Text] [Related]
18. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit.
Kenny O; Smyth TJ; Hewage CM; Brunton NP
Food Chem; 2013 Dec; 141(4):4295-302. PubMed ID: 23993618
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L.
Shivanagoudra SR; Perera WH; Perez JL; Athrey G; Sun Y; Wu CS; Jayaprakasha GK; Patil BS
Bioorg Med Chem; 2019 Jul; 27(14):3097-3109. PubMed ID: 31196754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
